NCT07250750 2026-02-11
Synergy-MG
ImmunAbs Inc.
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT06704269 2026-02-05
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis
Phase 1/2 Recruiting
NCT07022197 2025-06-15
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Tianjin Medical University General Hospital
Phase 1/2 Recruiting
NCT06106672 2025-02-13
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
COUR Pharmaceutical Development Company, Inc.
Phase 1/2 Recruiting
NCT02609022 2019-01-28
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
CuraVac
Phase 1/2 Completed
NCT00619671 2013-01-16
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
University of Vermont
Phase 1/2 Completed